InspireMD (NSPR) Q3 2026 earnings review
InspireMD wins US stent approval, but its cash runs low
InspireMD, a maker of mesh stents that prevent strokes, won FDA approval to return to the US market while its cash reserves shrank. Third-quarter sales fell 11% from a year ago because the May recall of its original US stent delivery system kept US revenue near zero. Overseas sales rose 9%, and summer job cuts reduced operating expenses by more than a quarter.
| Total revenue | $2.2M -11% from a year ago |
|---|---|
| International revenue | $2.2M +9% from a year ago |
| Gross margin | 10.7% 34.2% a year ago |
| Cash and marketable securities | $19.2M down $11.2M from last quarter |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because a major regulatory win is balanced by a tight cash clock. Chief executive Marvin Slosman secured FDA clearance in November for CGuard Prime in neck-access procedures, doubling the stent's US market and restarting US sales this quarter. The bad news: cash fell to $19 million — less than two quarters of spending by our math — and shifting overseas sales to cheaper countries cut gross margin to 11%.
The question now is whether the US relaunch can gain traction before InspireMD has to raise more money on tough terms. Either hospitals order the newly approved stent quickly and ease the funding pressure, or slow adoption forces a heavily dilutive capital raise within months. Fourth-quarter US sales and cash burn will tell.
🐂 Bull Case
FDA Clears Return to the US Market
InspireMD makes CGuard Prime, a mesh tube that props open clogged neck arteries to prevent strokes. In May, the medical device maker pulled its first US product off the market to fix its delivery catheter, which cut US sales to $32,000 this quarter.
In November, the US regulator approved a shorter version of CGuard Prime for transcarotid arterial revascularization (TCAR), a surgical method where doctors reach the artery directly through the neck. Chief executive Marvin Slosman called the clearance a "transformative milestone for InspireMD, enabling the launch of our next-generation carotid implant" that "paves the way for our return to the U.S. commercial market". The firm "expects to commence U.S. sales promptly in the fourth quarter of 2026".
The approval matters because it opens up more than 35,000 US procedures a year and stops a six-month drought in the company's highest-priced market. What to watch: fourth-quarter US revenue. A strong first few weeks of sales will show that hospitals still want the stent despite the earlier recall.
Job Cuts Lowered Operating Costs Ahead of Schedule
After pausing US sales in the spring, InspireMD cut about a fifth of its staff to save cash. Management previously said those job cuts would save $9 million a year starting in the fourth quarter, which by our math pointed to quarterly operating expenses near $11.4 million.
Spending fell much faster than that in the third quarter. Total operating costs dropped 26.7% from a year ago to $10.2 million. Excluding $1.1 million in one-off severance costs, by our math ongoing operating expenses fell to $9.1 million, down $4.6 million from the second quarter. Selling and marketing costs fell 67.3 percentage points of revenue, while administrative overhead dropped 79.4 percentage points.
What to watch: fourth-quarter selling and marketing expenses. As the company launches its newly approved neck-artery stent in the US, rising sales costs will show how much of the recent savings came from a temporary pause in US marketing.
🐻 Bear Case
Cash Covers Less Than Two Quarters of Spending
InspireMD relies on its cash reserves to fund clinical trials and product launches while it loses money every quarter. Despite lower operating expenses, the company spent $11.2 million of its cash and marketable securities in the third quarter, by our math, matching the second quarter's pace.
- Cash and marketable securities: $19.2 million on September 30, down from $54.2 million at the end of 2025
- Third-quarter net loss: $9.8 million, compared with $12.7 million a year ago
- Cash runway: about 1.7 quarters at the third-quarter spending rate, by our math
The company warns of "substantial doubt regarding its ability to continue as a going concern". Even if US sales restart quickly this winter, the profit from those first orders will not cover a $9 million quarterly expense base. InspireMD will need to raise fresh money before its redesigned original stent returns in the first half of 2027.
What to watch: financing announcements or share sales before year-end. Raising money right after the recent FDA approval would secure the balance sheet before reserves run low in early 2027.
Lower Overseas Prices Cut Into Gross Margin
With US sales paused during the third quarter, overseas hospitals brought in nearly all of InspireMD's money. Last quarter management said it was shifting its overseas business toward higher-margin markets, and this quarter the release praised "continued strong international performance".
The numbers tell the opposite story. Overseas sales growth slowed to 9.1% from a year ago, down from 21.2% in the second quarter and 48.0% in the first. Gross margin — the share of sales left after the cost of making the stents — fell 23.5 percentage points from a year ago to 10.7%, as manufacturing costs climbed to 89.3% of revenue. The company blamed the drop on the US recall and a "mix within international revenue to countries with a lower average sales price".
What to watch: fourth-quarter gross margin. Because US hospitals pay much more per stent than overseas distributors, the start of US sales should lift gross margin back above 20%.
Recalled Stent System Still Awaits FDA Filing
Carotid artery stenting (CAS) — threading a stent up from the groin or arm rather than through the neck — is the original US market InspireMD entered in 2025 before recalling its delivery catheter in May. The company has two paths back into that market: fixing the recalled CGuard Prime catheter, and winning FDA approval for its older CGuard system.
Neither has crossed the finish line yet. The fixed CGuard Prime catheter is "currently undergoing final validation and performance testing", with an FDA filing planned for December 2026 and a US return in the first half of 2027. Meanwhile, the release gave no target date for the older CGuard system, which management previously expected the FDA to rule on in the fourth quarter.
What to watch: confirmation in December that InspireMD submitted the FDA application for the fixed CAS catheter. Any delay past December would push the product's US return past the first half of 2027.
Risks this quarter didn't answer
Three standing risks from earlier quarters received no new numbers in the third-quarter earnings release.
- Hospital account retention: InspireMD hired Kathleen Kennedy to lead global sales, but did not say how many of its 100 prior US hospital accounts will buy the new TCAR stent without fresh committee reviews.
- Nasdaq listing compliance: maintaining compliance with stock exchange minimum price rules remains a listed risk, and the quarterly filing will show the current deadline.
- Single factory in Israel: the company makes all of its stents at one site in Israel, leaving supply exposed if regional conflict disrupts flights or staff.
💲 Other KPIs
Share count rose 16.5% from a year ago and 1.1% from the second quarter. Past stock and warrant sales funded the business through its US launch and recall, spreading the quarterly net loss across more shares.
Stock on hand rose 10.7% from the second quarter after falling for two straight quarters due to recall write-offs. The stent maker built up finished goods ahead of its fourth-quarter US launch for neck-access procedures.
Uncollected customer bills rose 4.4% from the second quarter, moving in line with overseas sales. Excluding last quarter's $734,000 recall credit adjustment, by our math total sales dipped 10.5% from the second quarter, so customer collections remain steady.
🔮 Guidance
Unchanged. The medical device group still plans to submit its fixed catheter design to the FDA before year-end, specifically in December 2026, and still targets a US relaunch in the first half of 2027. InspireMD has not issued numerical revenue guidance since withdrawing its full-year target in the spring.
❓ Key Questions
How will InspireMD fund operations into late 2027?
With $19.2 million in cash and an $11.2 million quarterly cash drop, reserves cover less than two quarters by our math. Investors need to know when and how management will raise capital now that the TCAR stent has FDA approval.
When will the FDA rule on the original CGuard?
Last quarter management expected a fourth-quarter FDA decision on the original CGuard stent for traditional CAS procedures. The third-quarter release gave no date, leaving unclear when InspireMD can sell in the traditional CAS market again.
What was third-quarter operating cash flow?
The earnings release did not include a cash flow statement. The quarterly filing will show how much of the $11.2 million cash drop came from ongoing operations versus severance payouts and recall credit settlements.
How many US hospitals are ready to order TCAR?
InspireMD had over 100 US hospital accounts before the May recall. Management has not said how many of those hospitals allow the new TCAR stent under existing approvals versus requiring a new committee vote.